Ligand Pharmaceuticals (LGND) has drawn fresh attention after recent trading, with the stock last closing at US$253.25. For investors, the focus now is on how this biopharmaceutical licensing model aligns with their portfolio goals.

The recent 1 day share price decline of 0.90% to US$253.25 comes after a strong run, with a 30 day share price return of 18.78% and a 1 year total shareholder return of 120.20%, suggesting momentum has been building rather than fading.

If Ligand Pharmaceuticals has sharpened your focus on high growth themes, it may be worth scanning other opportunities using our screener of 39 healthcare AI stocks.

With Ligand Pharmaceuticals trading at US$253.25 and an indicated intrinsic discount of about 33%, the key question is whether the current valuation still leaves room for upside or if the market is already pricing in future growth.

Most Popular Narrative: 8.8% Undervalued

At a last close of $253.25 against a narrative fair value of $277.60, the current view on Ligand Pharmaceuticals builds in some upside while anchoring that view on detailed royalty and growth assumptions.

Strong revenue and earnings growth are expected as Ligand broadens its high-margin royalty portfolio, with multiple partnered drugs (such as O2vir, Filspari, Qarziba, and Zelsuvmi) in various stages of commercialization or late-stage development. This expanding royalty base enhances recurring revenue, earnings visibility, and long-term cash flow predictability.

Curious what sits behind that projected royalty engine? The narrative leans on brisk revenue growth, thick margins, and a future earnings multiple that assumes sustained execution. The discount rate of 7.11% quietly does a lot of work in bringing those long dated cash flows back into today’s price.

Result: Fair Value of $277.60 (UNDERVALUED)

However, this Ligand Pharmaceuticals story still hinges on a concentrated royalty pool and ongoing pricing and regulatory pressure that could undercut those Filspari driven assumptions.

Next Steps

If this Ligand Pharmaceuticals discussion has you weighing both upside and risk, it pays to move quickly and pressure test the assumptions yourself using the 3 key rewards.

Looking for more investment ideas beyond Ligand Pharmaceuticals?

If Ligand Pharmaceuticals has sharpened your interest, do not stop here. Use focused stock lists to spot opportunities that align with your risk tolerance and income goals.

• Target potential mispriced opportunities by scanning 47 high quality undervalued stocks that combine solid fundamentals with room for a re rating.
• Strengthen the defensive side of your portfolio by reviewing solid balance sheet and fundamentals stocks screener (48 results) that may better withstand tougher conditions.
• Hunt for potential future leaders before they are crowded by institutions using our screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.